Back to search results

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Pancreatic Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

    Contact: Study coordinator (Colleen Apostol, RN) · GIClinicalTrials@jhmi.edu · 410-614-3644
    Contact: Principal Investigator (Eric Christenson, MD)
Study leads

  • Eric Christenson, MD

    Principal Investigator

    SKCCC • Johns Hopkins Medical Institution

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)